[Development and performance evaluation of a comprehensive genomic profiling assay for hematological malignancies]

Area of Science:

• Oncology
• Genetics
• Molecular Diagnostics

Context:

• Hematological malignancies require genetic alteration evaluation for clinical decision-making.
• No comprehensive genomic profiling (CGP) assays are currently approved in Japan for these cancers.
• Accurate genetic profiling is crucial for diagnosis, treatment selection, and prognosis.

Purpose:

• To develop and validate a novel CGP assay for hematological malignancies.
• To analyze mutations, structural variations, and fusion genes across 452 genes.
• To establish a cloud-based analysis and reporting system.

Summary:

• The HemeSight® CGP assay was developed, analyzing 452 genes for genetic alterations.
• It demonstrated high sensitivity, detecting genetic alterations at 5-10% allele frequency in non-clinical samples.
• Clinical validation showed high positive agreement: 94.4% for mutations, 94.7% for IGH rearrangements, and 100% for fusion genes.

Impact:

• HemeSight® offers a validated solution for comprehensive genomic profiling in Japanese hematological malignancy patients.
• This assay can improve diagnostic accuracy and personalize treatment strategies.
• It addresses a critical unmet need for approved genomic testing in Japan.